Explore News
-
Why GSK is Acquiring Nuvalent for $10.6 Billion
GSK’s acquisition of Nuvalent marks a significant move in the pharma industry
-
Why Novo and Lilly are Racing for GLP-1 Supremacy
Novo Nordisk and Eli Lilly rivalry intensifies in GLP-1 pill market
-
Weight Loss Drug Maker Sinks 25% After New Safety Data
Experimental weight loss drug meets targets but raises concerns over side effects
-
Abivax Stock Plunges 32% After Bowel Disease Drug Trial Update
Abivax’s stock plummeted after disappointing trial data
-
Eli Lilly Surges into Infectious Disease Market with $4 Billion Deals
Eli Lilly expands into infectious disease research with significant investments
-
AI Identifies 50% More Drug Combinations in Study
OpenAI-linked researchers leverage machine learning to predict dangerous drug pairings, potentially transforming patient
-
Why AstraZeneca is Investing £300m in UK Pharma
AstraZeneca pledges £300m investment in UK pharma sector
